SUBSCRIBE
SUBSCRIBE
News   Drug Development

Northfield Laboratories Blood Substitute Misses Phase 3 Trial Goals

May 23, 2007 | 
1 min read

CHICAGO, May 23 (Reuters) - Northfield Laboratories Inc. said on Wednesday that its red blood cell substitute, PolyHeme, failed to meet the primary goals of mortality and safety in a pivotal Phase III study.

Clinical research Phase III
MORE ON THIS TOPIC
Medical technology. Doctor holding health icon with dna, electronic medical record. Digital healthcare and research with global network connection on hologram virtual screen, insurance, digital health technology
Partnered
Ending the Diagnostic Odyssey for Patients
December 11, 2024
 · 
4 min read
 · 
BioSpace Insights
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
CAR-T
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
RSV
Moderna’s RSV Vaccines Run Into Safety Roadblock
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac